More than 45 encapsulated cell therapies and encapsulation technologies are being evaluated across different phase, By Roots Analysis Knowpia

Extensive research on cell encapsulation strategies has enabled the development of a variety of technologies capable of immobilizing / enclosing therapeutic entities within biocompatible matrices / carriers. Such products offer a myriad of advantages, and have demonstrated the capability to address existing challenges related to cell therapies and certain other types of interventions as well.

To order this 500+ page report, which features 170+ figures and 395+ tables, please visit this https://www.rootsanalysis.com/reports/249/request-sample.html

The USD 3.7 billion (by 2030) financial opportunity within the encapsulated cell therapies and encapsulation technologies market has been analyzed across the following segments:

§ Type of licensing deal payment

§ Upfront payment

§ Milestone payment

§ Therapeutic area

§ Metabolic disorder

§ Neurological disorder

§ Ophthalmic disorder

§ Oncological disorder

§ Target disease indication

§ Ataxia telangiectasia

§ Breast cancer

§ Diabetes

§ Glaucoma

§ Head and neck cancer

§ Macular telangectasia

§ Pancreatic cancer

§ Parkinson's disease

§ Retinitis pigmentosa

§ Type of encapsulation material used

§ Alginate-based microcapsule

§ Cellulose hydrogel

§ Medical-grade plastic

§ Red blood cell

§ Key geographical region

§ North America

§ Europe

§ Asia-Pacific and rest of the world

The Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030 report features the following companies, which we identified to be key players in this domain:

§ ALTuCELL

§ Azellon Cell Therapeutics

§ Beta-Cell

§ Betalin Therapeutics

§ CellProtect Biotechnology

§ Diatranz Otsuka

§ Encellin

§ EryDel

§ Gloriana Therapeutics

§ Living Cell Technologies

§ MaxiVAX

§ Neurotech Pharmaceuticals